Efficacy and safety of strontium ranelate in the treatment of osteoporosis in men

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 2, 2013, Pages 592-601

  Kaufman, J M ^a   Audran, M ^b   Bianchi, G ^c   Braga, V ^d   Diaz Curiel, M ^e   Francis, R M ^f   Goemaere, S ^a   Josse, R ^g   Palacios, S ^h   Ringe, J D ⁱ   Felsenberg, D ^j   Boonen, S ^k  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b ANGERS UNIVERSITY HOSPITAL   (France)

^c La Colletta Hospital Azienda Sanitaria   (Italy)

^d Rheumatology Department   (Italy)

^e Jimenez Diaz Foundation   (Spain)

^f NEWCASTLE UNIVERSITY   (United Kingdom)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h Instituto Palacios de Salud Y Medicina de la Mujer   (Spain)

ⁱ KLINIKUM LEVERKUSEN   (Germany)

^j CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^k UNIVERSITY OF LEUVEN   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BIOLOGICAL MARKER; PLACEBO; STRONTIUM RANELATE;

AGED; ANGINA PECTORIS; ARTICLE; BONE DENSITY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMUR NECK; GASTROINTESTINAL DISEASE; HEART MUSCLE ISCHEMIA; HIP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIMARY OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; SKIN MANIFESTATION;

AGED; AGED, 80 AND OVER; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DOUBLE-BLIND METHOD; HUMANS; MALE; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS; THIOPHENES; TREATMENT OUTCOME;

EID: 84873697417     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2012-3048     Document Type: Article

References (41)

1. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr Rev. 2008;29:441-464.
2. Kaufman JM, Goemaere S. Osteoporosis in men. Best Pract Res Clin Endocrinol Metab. 2008;22:787-812.
3. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726-1733.
4. Orwig DL, Chan J, Magaziner J. Hip fracture and its consequences: differences between men and women. Orthop Clin NorthAm. 2006; 37:611-622.
5. Swislocki A, Green JA, Heinrich G, et al. Prevalence of osteoporosis in men in a VA rehabilitation center. Am J Manag Care. 2010;16: 427-433.
6. Leboime A, Confavreux CB, Mehsen N, Paccou J, David C, Roux C. Osteoporosis and mortality. Joint Bone Spine 2101;77(Suppl 2): S107-S112.
7. Abraham A. Undertreatment of osteoporosis in men who have had a hip fracture. Arch Intern Med. 2003;163:1236-1237.
8. Westesson PL, Lee RK, Ketkar MA, Lin EP. Underdiagnosis and undertreatment of osteoporosis. Lancet. 2002;360:1891.
9. Donaldson MG, Cawthon PM, Lui LY, et al. Estimates of the proportion of older white men who would be recommended for phar-macologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res. 2010;25:1506-1511.
10. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604-610.
11. Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res. 2009;24:719-725.
12. Orwoll ES, Miller PD, Adachi JD, et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a onceweekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res. 2010;25:2239-2250.
13. Boonen S, Reginster J-Y, Kaufman JM, et al. Efficacy of once-yearly zoledronic acid 5 mg in men with osteoporosis with different levels of serum total testosterone [Abstract OC32]. Osteoporos Int. 2012; 23(suppl 2):S79 -S80.
14. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9-17.
15. Kaufman JM, Orwoll E, Goemaere S, et al. Teriparatide effects on vertebral fractures and bone mineral density in men with osteoporosis: treatment and discontinuation of therapy. Osteoporos Int. 2005;16:510-516.
16. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459-468.
17. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausalwomen with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90:2816-2822.
18. Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: results of a 5-year, randomized, placebo-controlled trial. Arthritis Rheum. 2008;58: 1687-1695.
19. Roux C, Fechtenbaum J, Kolta S, Isaia G, Andia JB, Devogelaer JP. Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis. Ann Rheum Dis. 2008;67:1736-1738.
20. Seeman E, Vellas B, Benhamou C, et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res. 2006;21:1113-1120.
21. Roux C, Reginster J-Y, Fechtenbaum J, et al. Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res. 2006;21:536-542.
22. Bruyere O, Roux C, Detilleux J, et al. Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate. J Clin Endocrinol Metab. 2007;92: 3076-3081.
23. Arlot ME, Jiang Y, Genant HK, et al. Histomorphometric and microCT analysis of bone biopsies from postmenopausal osteoporotic women treated with strontium ranelate. J Bone Miner Res. 2008; 23:215-222.
24. Chattopadhyay N, Quinn SJ, Kifor O, Ye C, Brown EM. The calcium-sensing receptor (CaR) is involved in strontium ranelate-induced osteoblast proliferation. Biochem Pharmacol. 2007;74:438-447.
25. Rizzoli R, Chapurlat RD, Laroche JM, et al. Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis: results of a 2-year study. Osteoporos Int. 2012;23: 305-315.
26. Marie PJ, Felsenberg D, Brandi ML. How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporos Int. 2011;22:1659-1667.
27. Committee for Medicinal Products for Human Use. Guideline on the evaluation of new medicinal products in the treatment of primary osteoporosis. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline/2009/09/WC500003405.pdf. Published November 16, 2006. Accessed June 12, 2012.
28. Kalender WA, Felsenberg D, Genant HK, Fischer M, Dequeker J, Reeve J. The European Spine Phantom-a tool for standardization and quality control in spinal bone mineral measurements by DXA and QCT. Eur J Radiol. 1995;20:83-92.
29. Hui SL, Gao S, Zhou XH, et al. Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments. J Bone Miner Res. 1997;12: 1463-1470.
30. Lu Y, Fuerst T, Hui S, Genant HK. Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos Int. 2001;12:438-444.
31. Marquis P, Cialdella P, De La Loge C. Development and validation of a specific quality of life module in post-menopausal women with osteoporosis: the QUALIOST. Qual Life Res. 2001;10:555-566.
32. Summary of product characteristics. Protelos. European Medicines Agency Web site. http://www.ema.europa.eu. Published 2006. Accessed June 12, 2012.
33. Szulc P, Munoz F, Duboeuf F, Marchand F, Delmas PD. Bone mineral density predicts osteoporotic fractures in elderly men: the MINOS study. Osteoporos Int. 2005;16:1184-1192.
34. Johnell O, Kanis JA, Oden A, et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res. 2005;20:1185-1194.
35. Bruyere O, Roux C, Badurski J, et al. Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate. Curr Med Res Opin. 2007;23:3041-3045.
36. Kanis JA, Bianchi G, Bilezikian JP, Kaufman JM, Khosla S, Orwoll E, Seeman E. Towards a diagnostic and therapeutic consensus in male osteoporosis. Osteoporos Int. 2011;22:2789-2798.
37. Ringe JD, Dorst A, Farahmand P. Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. Arzneimittelforschung. 2010;60:267-272.
38. Marquis P, Roux C, de la Loge C, et al. Strontium ranelate prevents quality of life impairment in post-menopausal women with established vertebral osteoporosis. Osteoporos Int. 2008;19:503-510.
39. Reginster JY, Kaufman JM, Goemaere S, et al. Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis. Osteoporos Int. 2011;23:1115-1122.
40. Liu JM, Wai-Chee KA, Pheng CS, et al. Efficacy and safety of 2 g/day of strontium ranelate in Asian women with postmenopausal osteoporosis. Bone. 2009;45:460-465.
41. Committee for Medicinal Products for Human Use. Summary of opinion (post authorisation): treatment of osteoporosis in men at increased risk of fracture. European Medicines Agency Web site. http://www.ema.europa.eu/docs/en-GB/ document-library/Summary-of-opinion/human/000560/WC500127765.pdf. Published May 24, 2012.